Analysts think CELC stock price could increase by 74%
Aug 30, 2024, 6:25 AM
-10.84%
What does CELC do
Celcuity, based in Minneapolis, employs 55 staff and went public on September 20, 2017. Its lead candidate, gedatolisib, targets specific cancer pathways and is in trials for advanced breast and prostate cancer.
8 analysts think CELC stock price will increase by 73.68%. The current median analyst target is $28.05 compared to a current stock price of $16.15. The lowest analysts target is $23.23 and the highest analyst target is $40.95.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
